Biosimilars: Opportunity or cause for concern?

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 3, 2007, Pages 405-410

  Roger, Simon D ^a   Mikhail, Ashraf ^b  

^a GOSFORD HOSPITAL   (Australia)

^b MORRISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHEON; ANTIBODY; CYTOKINE; ERYTHROPOIETIN ANTIBODY; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HORMONE; HUMAN GROWTH HORMONE; HUMAN INSULIN; INSULIN; INTERFERON; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PROTEIN ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT DNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE; BIOLOGICAL PRODUCT;

ANEMIA; BIOTECHNOLOGY; CLINICAL TRIAL; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; GOVERNMENT; HUMAN; IMMUNOGENICITY; NONHUMAN; PATENT; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SOCIOECONOMICS; DRUG CONTROL; ECONOMICS; IMMUNOLOGY; LEGAL ASPECT; PHARMACOKINETICS; STANDARD;

BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; PATENTS; QUALITY CONTROL; THERAPEUTIC EQUIVALENCY;

EID: 34848844984     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Committee for medicinal products for human use. Guideline on Similar Biological Medicinal Products. CHMP/437/04 2005. 2005.
2. C. S. Ben Maimon. Point: why biogenerics make sense. Nat Biotechnol, 24:268-269, 2006.
3. M. J. Belsey, L. M. Harris, R. R. Das, and J. Chertkow. Biosimilars: initial excitement gives way to reality. Nat Rev Drug Discov, 5:535-536, 2006.
4. M. Kuhlmann and A. Covic. The protein science of biosimilars. Nephrol Dial Transplant, 21 Suppl 5:v4-v8, 2006.
5. H. Schellekens. Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant, 20 Suppl 4:iv31-iv36, 2005.
6. H. Schellekens. How similar do 'biosimilars' need to be? Nat Biotechnol, 22:1357-1359, 2004.
7. A. J. Chirino and A. Mire-Sluis. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol, 22:13 83-1391, 2004.
8. D. Crommelin, T. Bermejo, M. Bissig, J. Damiaans, I. Kramer, P. Rambourg, G. Scroccaro, B. Strukelj, R. Tredree, and C. Ronco. Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist? Contrib Nephrol, 149:287-294, 2005.
9. H. Schellekens. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov, 1:457-462, 2002.
10. J. S. Robertson. Changes in biological source material. Biologicals, 34:61-63, 2006.
11. S. D. Roger. Biosimilars: how similar or dissimilar are they? Nephrology 11:341-346, 2006.
12. H. Schellekens. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther, 24:1720-1740, 2002.
13. H. Schellekens. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity. Eur J Clin Invest, 34:797-799, 2004.
14. F. Locatelli and S. Roger. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant, 21 Suppl. 5:v13-v16, 2006.
15. M. Kessler, D. Goldsmith, and H. Schellekens. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant, 21 Suppl 5:v9-v12, 2006.
16. H. Schellekens and N. Casadevall. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol, 251 Suppl 2:II4-II9, 2004.
17. A. J. Chirino, M. L. Ary, and S. A. Marshall. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today, 9:82-90, 2004.
18. H. P. Hartung, F. Munschauer, III, and H. Schellekens. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol, 12:588-601, 2005.
19. S. Malucchi, M. Capobianco, F. Gilli, F. Marnetto, M. Caldano, A. Sala, and A. Bertolotto. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. Neurol Sci, 26 Suppl 4:S213-S214, 2005.
20. F. Deisenhammer, H. Schellekens, and A. Bertolotto. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol, 251 Suppl 2:II31-II39, 2004.
21. I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clin Appl Thromb Hemost, 8:193-212, 2002.
22. J. Li, C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, and D. J. Kuter. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 98:3241-3248, 2001.
23. H. Schellekens. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol, 18:473-480, 2005.
24. N. Casadevall. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant, 17 Suppl 5:42-47, 2002.
25. N. Casadevall, J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayeux. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med, 346:469-475, 2002.
26. N. Casadevall. Pure red cell aplasia and antierythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant, 18 Suppl 8:viii37-viii41,2003.
27. H. Schellekens. Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micelles. Nephrol Dial Transplant, 19:2422, 2004.
28. K. Boven, J. Knight, F. Bader, J. Rossert, K. U. Eckardt, and N. Casadevall. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant, 20 Suppl 3:iii33-iii40, 2005.
29. K. Boven, S. Stryker, J. Knight, A. Thomas, M. van Regenmortel, D. M. Kemeny, D. Power, J. Rossert, and N. Casadevall. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int, 67:2346-2353, 2005.
30. A. Kromminga and H. Schellekens. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci, 1050:257-265, 2005.
31. H. Schellekens and W. Jiskoot. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol, 24:613-614, 2006.
32. A. Wiecek and A. Mikhail. European regulatory guidelines for biosimilars. Nephrol Dial Transplant, 21 Suppl 5:v17-v20, 2006.
33. A. Kavanaugh and E. C. Keystone. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol, 21:S203-S208, 2003.
34. E. Autret-Leca, L. souda-Grimaldi, A. P. Jonville-Bera, and F. Beau-Salinas. Pharmacovigilance of vaccines. Arch Pediatr, 13:175-180, 2006.
35. Committee for medicinal products for human use. Annex guideline on similar biological medicinal products containing biotechnology-Derived proteins as active substance: Non-clinical and clinical issues: Guidance on biosimilar medicinal products containing recombinant erythropoietins. European Medicines Agency. EMEA/CHMP/94526/2005 2005. 2005.